Tyra Biosciences expands board to ten, appoints Habib J. Dable as Class II director

Tyra Biosciences, Inc.

Board increased from nine to ten members; Dable appointed effective April 16, 2026, with term expiring at 2026 annual meeting.
Dable previously President & CEO of Acceleron Pharma (acquired by Merck in 2021) and advisor at RA Capital since April 2022.
Received option to purchase 44,400 shares vesting equally over 36 months; cash compensation per Non-Employee Director Program.
Board determined Dable is independent under Nasdaq listing requirements.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.